Zoetis (ZTS) Tops Q3 EPS by 10c; Issues Solid Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/22/2026
- S&P 500, Nasdaq end sharply lower as revived AI doubts ignite tech selloff
- Meta’s new Class C stock to keep Zuckerberg in California, fund AI spending spree
- Oil hits five-month high as Houthi attacks stoke supply fears
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
- Abbott plans to spin off its nutrition unit as a standalone public company
- Alphabet shares drop ahead of earnings next week
- AMD shares fall amid AI chip sector selloff
- Bloom Energy Corp. (BE) Tops Q3 EPS by 25c, Beats on Revenue; Offers FY26 Guidance
- JetBlue shares fall amid American results, fuel cost concerns
Zoetis (ZTS) PT Lifted to $58 at Piper Jaffray on Solid Q3 and Ahead of Simparica Approval
November 4, 2015 8:52 AM ESTPiper Jaffray analyst Kevin Ellich reiterated an Overweight rating and boosted his price target on Zoetis Inc. (NYSE: ZTS) to $58.00 (from $55.00) following solid Q3 results. The analyst sees Simparica approval coming soon.
Ellich commented, "ZTS' Q3 results were impressive as the company... More
Zoetis (ZTS) Announces 3Q Beat and Raise Along with PHARMAQ Deal; Guggenheim Reiterates Buy
November 3, 2015 1:17 PM ESTGuggenheim reiterated a Buy rating and $60.00 price target on Zoetis Inc. (NYSE: ZTS) following the company's 3Q15 earnings results. ZTS reported 3Q15 EPS of $0.50, $0.10 higher than consensus, and then increased its '15 and '16 EPS guidance to $1.70-$1.74 from $1.63-$1.68 and $1.84-$1.94 from $1.81-$1.93, respectively. The release also included the announcement of a deal with PHARMAQ. Management stated that PHARMAQ... More



